Response Assessment to Erythropoietin-Zeta (Epo-Alpha Biosimilar) Therapy in Low-Risk Myelodysplastic Syndromes

Background. This prospective observational study aimed to verify the efficacy of erythropoietin zeta in the treatment of patients with low-risk myelodysplastic syndrome. Methods. Patients with low/int-1 IPSS risk and serum erythropoietin level below 500 U/L were enrolled. Treatment consisted of eryt...

Descripción completa

Detalles Bibliográficos
Autores principales: Vetro, Calogero, Di Giacomo, Valeria, Mannina, Donato, Magrin, Silvana, Mulè, Antonio, Mitra, Maria Enza, Siragusa, Sergio, Duminuco, Andrea, Garibaldi, Bruno, Vadalà, Maria Cristina Emanuela, Di Raimondo, Francesco, Palumbo, Giuseppe A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8951463/
https://www.ncbi.nlm.nih.gov/pubmed/35329991
http://dx.doi.org/10.3390/jcm11061665

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8951463/
https://www.ncbi.nlm.nih.gov/pubmed/35329991
http://dx.doi.org/10.3390/jcm11061665

Ejemplares similares